Aripiprazole Long-Acting Injections (Abilify Maintena, Abilify Asimtufii, Aristada, Aristada Initio)
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PHAR.290 alerts
Get alerted when Policy MDN.CP.PHAR.290 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for long-acting injectable aripiprazole products (Abilify Maintena, Abilify Asimtufii, Aristada, Aristada Initio) for Meridian Health Plan members; applies to prescribers requesting coverage under the listed Meridian/Centene policies.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial therapy — Schizophrenia / Schizoaffective
Covered when ALL of the following are met for schizophrenia or schizoaffective disorder:
Approval duration 12 months
Initial therapy — Bipolar I disorder
Covered when ALL of the following are met for bipolar disorder:
Approval duration 12 months
Continuation criteria
Continued therapy covered when ALL of the following are met:
Approval duration 12 months
Product-specific coverage and dosing
Coverage and dosing guidance as described for specific products
Injection no sooner than 26 days after prior injection.
14 days oral overlap required at initiation.
Aristada Initio single 675 mg initiation dose; avoid same-muscle injections.
Non–FDA approved indications that are not addressed in this policy are not authorized for coverage unless the use is supported by the applicable off‑label policy (see CP.PMN.53 for Medicaid) or other evidence of coverage documentation. In addition, dementia‑related psychosis is specifically listed as a diagnosis for which coverage is not authorized under this policy.
When this clinical policy conflicts with state Medicaid coverage provisions for a Medicaid member, the state Medicaid provisions take precedence. Providers should follow the state Medicaid manual for any coverage requirements or exceptions that apply to this policy.
Use of aripiprazole long‑acting injectables for dementia‑related psychosis is explicitly not authorized. This reflects the documented boxed warning regarding increased mortality in elderly patients with dementia‑related psychosis and is therefore a contraindicated/unsupported indication in this policy.
Initial Therapy Criteria
Initial therapy — Initial use criteria by indication
Initial use criteria by indication
Initiation criteria — Initiation criteria differ by product
Initiation requirements differ by product
Can replace next scheduled Abilify Maintena injection with Asimtufii 960 mg.
Continuation / Maintenance Criteria
Continued therapy — Continued coverage conditions
Continued coverage conditions
Maintenance dosing — Maintenance dosing guidance per product
Maintenance dosing guidance per product
Coding
Provider Actions and Requirements
Prior authorization required with criteria-based documentation
Prior authorization is required. Prescribers must submit a prior authorization request that documents the member meets the stated initial or continued therapy criteria, and must provide documentation of a coordinated follow-up outpatient appointment for administration of the next LAI dose when requesting approval.
- PA must demonstrate member meets all applicable initial or continuation criteria (diagnosis, prescriber involvement, age, adherence/history or recent inpatient initiation).
- Prescriber must provide documentation of the follow-up outpatient appointment with the PA request.
PA submissions must reference HCPCS codes and exact product/dose
Include HCPCS codes and the exact product and dose in PA/billing documentation; use the HCPCS codes referenced in the policy and document product strength and dosing regimen.
Consider therapeutic alternatives (oral aripiprazole/other antipsychotics)
Therapeutic alternatives such as oral aripiprazole (and other antipsychotics listed in the policy table) may be considered or required per formulary and PA processes prior to LAI use.
- Oral aripiprazole dosing examples are provided (e.g., 10–15 mg PO QD; up to 30 mg/day) as alternatives in the policy.
- Formulary/PA rules may require trial of listed oral alternatives before approving LAI therapy.
Observe required oral overlap when initiating certain LAI products
Follow product-specific initiation instructions for oral overlap: some LAI products require concomitant oral aripiprazole for a defined period when initiating therapy.
- Abilify Asimtufii: administer with oral aripiprazole (or another tolerated oral antipsychotic) for the first 14 consecutive days.
- Aristada initiation options may require oral aripiprazole for up to 21 days depending on regimen; Aristada Initio is given with a single 30 mg oral aripiprazole dose when used as the initiation method.
Submit required clinical documentation with PA requests
Provide clinical documentation supporting that the member meets all approval criteria, including diagnosis, prescriber consultation, age, history of non-adherence or inpatient initiation, established tolerability to oral aripiprazole when required, and coordination of follow-up appointment.
- Acceptable documentation includes office chart notes, lab results, or other clinical information.
- When oral tolerability is required (e.g., history of non-adherence with established tolerability to oral aripiprazole), include documentation of tolerability.
Billing: use HCPCS J0401, J1943, J1944 and record product strength/dosing
Use the specified HCPCS codes for claims and document product strength and dosing regimen precisely on billing and in clinical documentation.
- HCPCS codes: J0401 (aripiprazole, extended release, 1 mg), J1943 (aripiprazole lauroxil, Initio, 1 mg), J1944 (aripiprazole lauroxil, Aristada, 1 mg).
- Document the exact product strength and regimen (examples: Abilify Maintena 300 mg or 400 mg; Abilify Asimtufii 720 mg or 960 mg; Aristada 441–1064 mg; Aristada Initio 675 mg).
Incomplete documentation or non‑covered indications may trigger denial
Requests lacking documentation that the member meets approval criteria—or requests for non‑covered indications such as dementia‑related psychosis—may be denied.
- Denials may result if diagnosis, prescriber consultation, age, evidence of prior adherence/non‑adherence, inpatient initiation history, or follow-up appointment documentation are missing.
- Coverage is not authorized for dementia‑related psychosis; such requests should be expected to be denied.
Follow state Medicaid provisions when they conflict with this policy
When state Medicaid coverage provisions conflict with this policy, the state Medicaid provisions take precedence; follow the applicable state Medicaid manual provisions.
- For Medicaid members, adhere to state Medicaid manual coverage provisions that supersede this clinical policy when conflicts exist.
- Failure to follow applicable state Medicaid provisions may result in denial.
Step Therapy and Alternatives
| Therapeutic alternative | Typical oral dosing / notes | Coverage status |
|---|---|---|
| Aripiprazole (Abilify) — oral | ||
| 10–15 mg PO once daily (typical starting dose for bipolar disorder and schizophrenia); maximum 30 mg/day | ||
| Oral aripiprazole may be considered as a step therapy alternative per formulary/PA |
| Product / initiation method | Oral overlap / initiation instructions | Notes |
|---|---|---|
| Aristada — alternative initiation (oral overlap) / other regimens | ||
| Some Aristada regimens are initiated with oral aripiprazole for 21 consecutive days when starting from certain dosing schedules | ||
| Dosing options include monthly (441, 662, 882 mg), every 6 weeks (882 mg), or every 2 months (1064 mg); dose adjustments for CYP interactions/poor metabolizers |
Quantity Limits and Available Strengths
Site of Care and Administration
Administer Aristada Initio IM (deltoid or gluteal); timing for subsequent Aristada specified
Aristada Initio must be administered as a single IM injection in the deltoid or gluteal muscle; the first Aristada injection may be given the same day or up to 10 days after Initio, with subsequent timing per product labeling.
- Aristada Initio dose: 675 mg IM (deltoid or gluteal).
- First Aristada injection: same day or within 10 days after Initio.
Inject IM per labeling and avoid same‑muscle injections for Aristada/Initio
Administer intramuscular injections per product labeling into the deltoid or gluteal muscle and avoid injecting Aristada and Aristada Initio into the same muscle.
- Do not inject both Aristada and Aristada Initio into the same deltoid or gluteal muscle.
Definitions
Background
Aripiprazole long‑acting injectables include formulations of aripiprazole monohydrate and aripiprazole lauroxil and are second‑generation (atypical) antipsychotic LAIs indicated primarily for the treatment of schizophrenia in adults. Selected formulations (Abilify Maintena and Abilify Asimtufii) are also indicated for maintenance treatment of bipolar I disorder in adults. These LAIs are commonly used to address adherence challenges with oral therapy or to continue therapy after inpatient initiation, and product selection and dosing follow specific labeling and monitoring requirements.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.